VOYDEYA

Indicated For

Paroxysmal nocturnal hemoglobinuria (PNH) with extravascular hemolysis

About This Medication

# Alexion OneSource Patient Guide: How to Get VOYDEYA (danicopan) at Low or No Cost VOYDEYA (danicopan) is a prescription medication used to treat certain rare conditions, and the **Alexion OneSource** program from Alexion helps eligible patients access it through copay assistance and support services, potentially reducing costs to as low as $0 for commercially insured individuals.[1][6][7] This guide explains everything you need to know about qualifying for and using the program in simple terms. It's designed for patients like you who may be facing high costs for this important treatment. ## About VOYDEYA (danicopan) **VOYDEYA (danicopan)** is an oral complement inhibitor developed by Alexion (now part of AstraZeneca Rare Disease) to help manage specific rare diseases, often used in combination with other therapies like ULTOMIRIS or SOLIRIS for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS).[1][4][5] It works by blocking the alternative complement pathway to reduce hemolysis and prevent complications. Always consult your doctor for personalized information on why VOYDEYA is prescribed for you, including risks like infections—your provider must ensure you're vaccinated against meningococcal bacteria before starting.[4][5] Alexion's OneSource program supports patients on VOYDEYA and other Alexion products with education, insurance navigation, and financial help. It's free to enroll and available nationwide in the US.[1][3] ## Who Qualifies for Alexion OneSource? The program is open to US patients prescribed Alexion medications like VOYDEYA, but financial assistance (copay help) has strict rules:[7] - **Commercial insurance only**: You must have private insurance (not government-funded). Eligible patients may pay **$0 out-of-pocket** for medication and some infusion costs (if applicable), up to an annual maximum that varies by product and plan.[6][7] - **No federal programs**: Medicare, Medicaid, Medicare Advantage, TRICARE, VA, or similar are **not eligible** due to federal laws preventing manufacturers from assisting government-insured patients.[7] - **Valid prescription**: For an FDA-approved use of VOYDEYA.[7] - **State exceptions**: In Massachusetts or Rhode Island, medication copay help is available, but not infusion costs.[7] OneSource also offers non-financial support (education, resources) to **all** US patients regardless of insurance.[3][5] ## Income Eligibility Breakdown Alexion OneSource **does not use income thresholds** for copay assistance—eligibility focuses on insurance type and prescription validity.[7] However, if you're uninsured or underinsured, explore Alexion's patient assistance program for free medication (separate from copay help).[9] Here's a simple table summarizing key eligibility factors: | Factor | Eligible? | Details | |--------|-----------|---------| | **Commercial Insurance** | **Yes** | Copay assistance up to annual max; as low as $0 copay.[7] | | **Medicare/Medicaid** | **No** | Federal rules prohibit manufacturer copay programs.[7] | | **Uninsured** | **Partial** | Free meds via patient assistance (not copay); contact OneSource.[9] | | **Income Limits** | **None specified** | No household income caps for copay; varies for free med program.[7][9] | | **US Resident** | **Yes** | Program for US patients only.[3] | If your income is low, ask OneSource about free medication options through Alexion Pharmaceuticals Patient Assist.[9] ## Insurance Requirements **Commercially insured patients** qualify for the copay program, covering out-of-pocket medication (and infusion where applicable) costs.[6][7] Government insurance excludes you from copay help—alternatives include state programs or low-income subsidies.[7] Your plan's terms affect the benefit maximum. OneSource helps verify coverage and appeal denials.[1][3] ## Step-by-Step Application Process Applying is straightforward with multiple methods. Start by contacting OneSource—they guide you personally.[1][2] 1. **Talk to your doctor**: Confirm VOYDEYA prescription and complete any required safety steps (e.g., meningococcal vaccination).[4] 2. **Enroll in OneSource**: Call **1-888-765-4747** (8:30 AM–8 PM ET; urgent line available) or email OneSource@alexion.com. Download the enrollment form if needed.[2][3] 3. **Submit for copay assistance**: Your provider may need to fill out forms. Fax to 1-800-420-5150 or email. Alexion reviews quickly.[2][6] 4. **Provide insurance details**: Share your insurance card; no extensive docs usually needed for copay (varies).[7] 5. **Get approval**: OneSource coordinates benefits. Medication ships via **Onco360 specialty pharmacy** to your home.[program details] For inpatient starts, there's a separate program with free initial doses.[2] ## Timeline and Delivery - **Processing**: Often quick—urgent requests handled outside business hours. Expect approval in days; OneSource communicates next steps.[2] - **Delivery**: VOYDEYA ships directly to you via **Onco360 specialty pharmacy** for home convenience. Refills coordinated through them.[program details][10] Track via your OneSource team.[5] ## Alternatives if Denied or Ineligible - **Government insurance**: Use Extra Help (Medicare), state aid, or 340B clinics. - **Uninsured/low-income**: Alexion free drug program—call OneSource for details.[9] - **Appeals**: OneSource assists with insurance appeals.[1] - **Other help**: Patient Access Network (PAN), HealthWell Foundation, or NeedyMeds for rare disease funds. - **Biosimilars**: None currently listed for VOYDEYA.[program details] ## Important Disclaimer This guide is for informational purposes only and based on publicly available program details as of general knowledge. Eligibility, benefits, and terms can change—**always contact Alexion OneSource at 1-888-765-4747 or OneSource@alexion.com for the latest info**. Not medical advice; consult your healthcare provider. Program not health insurance. Alexion determines eligibility solely.[1][7] (Word count: 1028)

Program information last verified: March 30, 2026